HSBC has maintained a ‘Buy’ rating on Lupin, setting a target price of ₹2,565 per share, implying a 26.6% upside potential from the current market price of ₹2,025.25.
The brokerage notes that Lupin’s Q3 performance was operationally in line with expectations, and based on 9MFY25 results, the company expects full-year EBITDA margins of 23-23.5%.
HSBC expects a strong earnings trajectory, driven by key US product launches and the continued build-up of a complex generics pipeline in the US. The firm has factored in a 26.5% EPS CAGR over FY24-27, reinforcing its bullish outlook on Lupin.
With a focus on margin expansion, US market growth, and a solid product pipeline, HSBC remains optimistic about Lupin’s long-term potential.
Disclaimer: The above article is for informational purposes only and does not constitute financial advice. Investors are advised to consult their financial advisors before making any investment decisions.